Tiziana Life Sciences Ltd (NASDAQ:TLSA) does about 273.53K shares in volume on a normal day but saw 921756 shares change hands in the recent trading day. The company now has a market cap of 109.53M USD. Its current market price is $0.99, marking an increase of 6.50% compared to the previous close of $0.93. The 52 week high reached by this stock is $1.74 whilst the lowest price level in 52 weeks is $0.41.
Tiziana Life Sciences Ltd (TLSA) has a 20-day trading average at $0.9663 and the current price is -43.11% off the 52-week high compared with 141.41% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.9531 and its 200-day simple moving average is $0.8586. If we look at the stock’s price movements over the week, volatility stands at 7.07%, which decreases to 7.06% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 53.58 to suggest the stock is neutral.
The consensus objective for the share price is $3.00, suggesting that the stock has a potential upside of 67.0% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on December 22, 2020 when B. Riley Securities initiated the stock to “Buy” and issued a price target of $8.
The current price level is 2.43%, 3.85%, and 15.28% away from its SMA20, SMA50, and SMA200 respectively, with the TLSA price moving below the 50-day SMA on current market day. Tiziana Life Sciences Ltd (TLSA) stock is up 0.68% over the week and 11.15% over the past month. Its price is 76.75% year-to-date and 73.89% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year.
To reach the target analysts have set, the stock logically needs to grow 67.0 percent from here.
The beta has a value of 0.63.
